AstraZeneca Sues Sun to Block Copies of Three Diabetes Drugs

AstraZeneca PLC filed three lawsuits seeking to block Sun Pharmaceutical Industries Ltd.’s proposed copies of its Farxiga, Qtern, and Xigduo XR diabetes treatments, alleging each infringes a patent that won’t expire until October 2025.

Cambridge, England-based AstraZeneca filed the complaints Monday in the US District Court for the District of Delaware, where they were docketed Tuesday. Each alleges the targeted generic drug infringes US Patent No. 6,515,117, related to compounds and methods for treating diabetes and related diseases.

The patent was the focus of an October 2021 ruling in which Judge Richard G. Andrews rejected arguments by Zydus Lifesciences ...